1Goy BW, Lee SP, Eilber F, et al. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors [ J ]. Int J Radiat Oncol Biol Phys, 1997,39:659-665.
2Sturt JNH, Clark SK. Current ideas in desmoid tumors [ J]. Faro Cancer,2006,5:275-285.
4Tejpar S, Li C, Yu C,et al. Tcf-3 expression and beta-catenin mediated transcriptional activation in aggressive fibromatosis ( desmoid tu,nour ) [J]. Br J Cancer, 2001,85 : 98- 101.
5Cheon SS,Cheah AY,Turley S,et al. Beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds [J]. Proc Natl Acad Sci U S A,2002,99:6973-6978.
6Saito T, Oda Y, Kawaguchi K, et al. Possible association between higher beta-catenin mRNA expression and mutated beta-catenin in sporadic desmoid tumors: realtime semiquantitative assay by Taq Man polymerase chain reaction[ J ]. Lab Invest ,2002,82:97-103.
7Sharma H, Sen S, Sheriff AK, et al. Characterization of apoptosis-related molecular changes in a desmoid tumor of the chest wall : report of a case [ J ]. Surg Today,2003,33 : 3558-3562.
8Tolg C, Poon R, Fodde R, et al. Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive fibromatosis ( desmoid tumor) [ J ]. Oncogene ,2003,22 : 6873-6882.
9Lucas DR, alAbbadi M,Tabaczka P, et al. c-Kit expression in desmoid fibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies [ J ]. Am J Clin Pathol, 2003,119 : 339-345.
10Church J, Berk T, Boman BM,et al. Staging intra-abdominal desmoid tumors in familial adenomatous polyposis:a search for a uniform approach to a troubling disease [ J ]. Dis Colon Rectum,2005,48 : 1528-1534.
二级参考文献24
1Wang CP, Chang YL, Ko JY, et al. Desmoid tumor of the head and neck[J]. Head Neck, 2006, 28(11):1008-1013.
2Goy BW, Lee SP, Eilber F, et al. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors [J]. Int J Radiat Oncol Biol Phys, 1997, 39(3):659-665.
3Caspari R, Olschwang S, Friedl W, et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444[J]. Hum Mol Genet, 1995, 4(3): 337-340.
4Friedl W, Caspari R, Sengteller M, et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families[J]. Gut, 2001, 48(4):515-521.
5Wilcken N, Tattersall MH. Endocrine therapy for desmoid tumors[J]. Cancer, 1991, 68(6): 1384-1388.
6Dhingra K.Antiestrogens-tamoxifen, SERMs and beyond[J]. Invest New Drugs, 1999, 17(3): 285-311.
7Leithner A, Gapp M, Radl R, et al. Immunohistochemical analysis of desmoid tumours[J]. J Clin Pathol, 2005,58(11): 1152-1156.
8Lim CL, Walker M J, Mehta RR, et al. Estrogen and antiestrogen binding sites in desmoid tumors[J]. Eur J Cancer Clin Oncol, 1986, 22(5): 583-587.
9Sφrensen A, Keller J, Nielsen OS, et al. Treatment of aggressive fibromatosis: a retrospective study of 72 patients followed for 1-27 years[J]. Acta Orthop Scand, 2002, 73 (2):213-219.
10Micke O, Seegenschmiedt MH. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national patterns of care study[J]. Int J Radiat Oncol Biol Phys, 2005, 61(3):882-891.
